VanEck Pharmaceutical ETF $PPH Shares Sold by Adamsbrown Wealth Consultants LLC

Adamsbrown Wealth Consultants LLC lowered its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 30.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 136,899 shares of the company’s stock after selling 59,077 shares during the quarter. VanEck Pharmaceutical ETF makes up approximately 3.4% of Adamsbrown Wealth Consultants LLC’s holdings, making the stock its 10th biggest holding. Adamsbrown Wealth Consultants LLC owned approximately 1.09% of VanEck Pharmaceutical ETF worth $12,370,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Belpointe Asset Management LLC increased its position in VanEck Pharmaceutical ETF by 42.2% during the third quarter. Belpointe Asset Management LLC now owns 8,113 shares of the company’s stock valued at $733,000 after acquiring an additional 2,409 shares during the last quarter. AAFMAA Wealth Management & Trust LLC boosted its position in VanEck Pharmaceutical ETF by 2.4% during the third quarter. AAFMAA Wealth Management & Trust LLC now owns 40,000 shares of the company’s stock worth $3,614,000 after acquiring an additional 919 shares during the last quarter. J.Safra Asset Management Corp grew its holdings in shares of VanEck Pharmaceutical ETF by 4.4% during the 3rd quarter. J.Safra Asset Management Corp now owns 285,787 shares of the company’s stock worth $25,824,000 after purchasing an additional 12,011 shares during the period. Hudock Inc. increased its position in shares of VanEck Pharmaceutical ETF by 6.7% in the 3rd quarter. Hudock Inc. now owns 9,830 shares of the company’s stock valued at $888,000 after purchasing an additional 613 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in shares of VanEck Pharmaceutical ETF by 82.4% during the second quarter. Osaic Holdings Inc. now owns 22,125 shares of the company’s stock worth $1,946,000 after acquiring an additional 9,992 shares during the last quarter.

VanEck Pharmaceutical ETF Trading Up 0.2%

Shares of PPH opened at $107.27 on Wednesday. VanEck Pharmaceutical ETF has a 12-month low of $77.67 and a 12-month high of $108.26. The stock has a market cap of $1.22 billion, a P/E ratio of 20.21 and a beta of 0.54. The company has a 50-day moving average of $103.00 and a two-hundred day moving average of $94.53.

VanEck Pharmaceutical ETF Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 31st. Shareholders of record on Monday, December 29th were issued a dividend of $0.3106 per share. This represents a $1.24 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, December 29th.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.